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GYN clinic housed in a University of Massachusetts 
Medical School affiliated teaching hospital. Both 
sites serve primarily Medicaid-eligible patients. Site 
1 has a Healthy Start grant,8 which provides routine 
periodic depression screening and case management
to most pregnant patients. Site 2 performs depression
screening for about 1 in 5 patients, based on staff 
concerns about particular patients. Neither site 
screens for other mood disorders. Women who 
screen positive in any area are offered a free interview
with a trained clinician to assess for further risk and 
to make appropriate referrals.
Results
The project has screened 139 women to date, 73% of 
whom were seen during prenatal visits.
PMD screening. Forty (29%) of the women screened 
to date have screened positive for symptoms of 
depression, anxiety, or posttraumatic stress. Of these 
40, 85% were positive for depression, 48% had 
anxiety symptoms, and 53% had PTSD symptoms. 
One in 5 women were comorbid with at least two 
of these areas, and 1 in 3 women were comorbid 
with all three areas. Of note, 15% of the 40 women 
screened positive for anxiety and/or PTSD, and 
did not screen positive for depression. Also of note, 
90.5% of the women referred for treatment were 
being seen for prenatal rather than postnatal care.
Biological Risk Factor Questionnaire (BRFQ). The 
5-item BRFQ totals correlated significantly with 
the depression (.35), anxiety (.36), and PTSD scale 
totals (.36). Women with a history of counseling 
Postpartum mood disorders (PMDs) affect new mothers and their ability to care for their 
newborns.1  An estimated 50-80% of all mothers
experience “baby blues”,2 and 10-28% of new 
mothers experience an episode of postpartum 
depression (PPD).2-4 Little research has examined 
the prevalence of PMDs other than PPD. With 
proper identification and referral, medication and 
psychotherapy have been shown to be effective 
treatments for PMDs.5, 6 However, in the absence of 
systematic screening, most PMDs are not detected.7
Specific Aims
With the aid of a grant from UMMS Commonwealth 
Medicine, the Prenatal Emotional Health Screening 
(PEHS) project was established to examine (1) 
the prevalence of PMDs other than depression 
(specifically, anxiety and PTSD), (2) biological risk 
factors which contribute to PMD development, and 
(3) the impact of systematic screening on PMD 
identification and referrals. The project screens for 
anxiety, depression and posttraumatic symptoms, 
and administers a 5-item Biological Risk Factor 
Questionnaire (BRFQ). The BRFQ assesses putative 
biological risk factors for PMD's such as personal 
and family history of depression, and mood changes 
related to shifts in women's hormones. The PEHS 
project also seeks to determine the overall feasibility 
of such routine screening in OB-GYN prenatal care 
settings. 
Currently, the study is ongoing in two sites: (1) a 
community-based health center and (2) an OB-
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for depression, a mother who suffered from depression, 
a history of premenstrual mood changes, or past PPD 
reported significantly higher scores for depression, anxiety, 
and symptoms of PTSD. 
Referrals. After a one-session interview, about half (n=21) 
of the women who screened positive on at least one 
screening measure were referred for treatment. Most 
(90.5%) of the 21 women referred for treatment had 
screened positive for depression, although 76% of them 
had screened positive for PTSD and 52% for anxiety. If a 
woman originally screened positive for depression, there 
was a 54% chance she would be referred for treatment. If 
she screened positive for anxiety, there was a 58% chance 
of being referred, and if she screened positive for PTSD, 
there was a 76% chance of being referred (see figure 1). 
Note that there were participants who screened positive 
on one or more of the scales in the primary interview 
but refused the secondary screening and therefore the 
possibility of referral for treatment.  Some of these women 
refused the secondary screen because they were already 
getting psychiatric treatment. 
Discussion and Future Directions
Our preliminary results point to the high prevalence (15%) 
of a range of mood problems among low income pregnant, 
pre- and postpartum women. A depression-only screen 
appears to identify an unexpectedly high proportion of 
women with potentially serious mood problems (regardless 
of the presence or absence of anxiety or PTSD). However, 
women who were comorbid for both depression and 
PTSD, were far more likely to be referred for treatment 
than those who were not. These results point to the utility 
of incorporating a brief depression screen into standard 
pre- and postnatal care (something already being done 
through Healthy Start initiatives).
Anxiety and PTSD screens can be somewhat labor intensive 
to administer and score in a busy OB-GYN setting, 
making them an impractical addition to practice as usual. 
In contrast, the 5-item BRFQ, which asks women simple 
questions about their personal and family medical and 
psychiatric history, appears to have useful predictive value 
when assessing women for PMDs and may be simple for 
obstetrical providers to incorporate into standard care if it 
turns out to have predictive value. It could then be used by 
obstetrical providers to flag patients at risk for perinatal 
psychiatric illness and to concentrate intensive screening 
efforts on women who are most at risk.
Further analysis will help determine whether screening 
women while pregnant for symptoms and risk factors for 
psychiatric illness is useful. While current standards of 
practice call for screening only at the six week postpartum 
visits and not at other perinatal visits, initial project results 
suggest that many of the pregnant women with psychiatric 
needs can be captured in the prenatal period, increasing 
opportunities for intervention and prevention. 
